Sanofi (NASDAQ:SNY) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its position in Sanofi (NASDAQ:SNY) by 7.1% during the third quarter, HoldingsChannel.com reports. The fund owned 254,738 shares of the company’s stock after acquiring an additional 16,780 shares during the quarter. Geode Capital Management LLC’s holdings in Sanofi were worth $14,681,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its stake in Sanofi by 31.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after buying an additional 33,105 shares in the last quarter. GFS Advisors LLC lifted its stake in Sanofi by 1,017.9% in the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after buying an additional 11,655 shares in the last quarter. Legacy Capital Wealth Partners LLC lifted its stake in shares of Sanofi by 114.2% during the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock worth $1,399,000 after purchasing an additional 12,942 shares during the period. Icon Wealth Advisors LLC lifted its stake in shares of Sanofi by 7,954.4% during the 3rd quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock worth $16,873,000 after purchasing an additional 289,144 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Sanofi during the 3rd quarter worth $8,728,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on SNY shares. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Trading Down 1.0 %

Shares of SNY opened at $48.23 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $122.40 billion, a P/E ratio of 24.61, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. The stock’s fifty day simple moving average is $49.64 and its 200 day simple moving average is $52.03. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the company posted $2.55 EPS. On average, equities research analysts forecast that Sanofi will post 4.06 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.